Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Report Type

Organization

Disposition

Year

Month

Found 72808 record(s)

Req # A-2024-000007

Adverse Drug Reactions (ADRs) for Heparin. Report numbers: 001072985.

Organization: Health Canada

8 page(s)
April 2024

Req # A-2024-000012

Adverse Drug Reactions (ADRs). Report numbers: 001067949, 001069982.

Organization: Health Canada

17 page(s)
April 2024

Req # A-2024-000017

Adverse Drug Reaction (ADR) for ACITRETIN. Report number: 1071472. ADRs for ANASTROZOLE. Report numbers: 983160, 990116. ADR for CIPROFLOX. Report number: 1032025. ADR for Clonidine. Report number: 981372. ADRs for EPLERENONE. Reports number:…

Organization: Health Canada

70 page(s)
April 2024

Req # A-2024-000028

Adverse Drug Reactions (ADRs) for Rosuvastatin-40. Report numbers: 000657015, 000702528. ADRs for Rosuvastatin-10. Report numbers: 000675846, 000928844. ADRs for Rosuvastatin-5. Report numbers: 000698101, 000705573. ADRs for Rosuvastatin-20. Report…

Organization: Health Canada

29 page(s)
April 2024

Req # A-2024-000032

Adverse Drug Reactions (ADRs) for IBUPROFEN. Report numbers: 001049833, 001051635, 001052031, 001052040, 001052619, 001050859, 001053224, 001055320, 001065019, 001065607.

Organization: Health Canada

76 page(s)
April 2024

Req # A-2024-000068

Adverse Drug Reaction (ADR) for YESCARTA. Report number: 001076510.

Organization: Health Canada

3 page(s)
April 2024

Req # A-2022-02096

Any/all records of the application criteria for new Board Members at the IRB from the time that public servant decision makers replaced GIC appointed decision makers at the RPD, and records of any changes/modifications to the RPD decision maker…

Organization: Immigration and Refugee Board of Canada

97 page(s)
April 2024

Req # A-2023-01721

Please provide redacted electronic copies of the written reasons for the following RPD decisions. TC2-38008; TC0-03751; TC2-25976; TC3-00379; TC3-09187; TC2-07922; TC2-35150; TC0-06106; TC1-21297; TC2-04580; TC3-09332; TC3-19445; TC3-23063; TC3-…

Organization: Immigration and Refugee Board of Canada

414 page(s)
April 2024

Req # A-2021-41844

All records (including but not limited to draft and final policies, guidelines, privacy impact assessments, meeting notes, technical specifications, training documents, bulletins, memoranda, and all internal and external correspondence, including e-…

Organization: Immigration, Refugees and Citizenship Canada

26 page(s)
April 2024

Req # A-2021-42540

Recommendations for designation provided by National Angel Capital Organization (NACO) since 2018 - (Until January 20, 2022) Recommendations for designation provided by Canadian Venture Capital & Private Equity Association (CVCA) since 2018 - (…

Organization: Immigration, Refugees and Citizenship Canada

89 page(s)
April 2024
Date modified: